KELUN PHARMA(SZ:002422) Xin Lang Cai Jing·2025-11-12 01:31Group 1 - On November 11, Kelong Pharmaceutical experienced a decline of 1.79% with a trading volume of 312 million yuan. The financing buy amount for the day was 41.75 million yuan, while the financing repayment was 13.71 million yuan, resulting in a net financing buy of 28.04 million yuan. As of November 11, the total financing and securities lending balance was 916 million yuan [1] - The financing balance of Kelong Pharmaceutical was 912 million yuan, accounting for 1.77% of the circulating market value, which is above the 60th percentile level over the past year, indicating a relatively high position [1] - In terms of securities lending, Kelong Pharmaceutical repaid 2,100 shares and sold 5,800 shares on November 11, with a selling amount of 187,500 yuan. The remaining securities lending volume was 12,000 shares, with a balance of 3.88 million yuan, also exceeding the 60th percentile level over the past year [1] Group 2 - As of September 30, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% compared to the previous period. The average circulating shares per person decreased by 7.70% to 35,200 shares [2] - For the period from January to September 2025, Kelong Pharmaceutical reported operating revenue of 13.28 billion yuan, a year-on-year decrease of 20.92%. The net profit attributable to the parent company was 1.20 billion yuan, down 51.41% year-on-year [2] - Kelong Pharmaceutical has distributed a total of 6.90 billion yuan in dividends since its A-share listing, with 3.59 billion yuan distributed over the past three years [2] Group 3 - As of September 30, 2025, among the top ten circulating shareholders of Kelong Pharmaceutical, China Europe Medical Health Mixed A ranked as the third-largest shareholder with 40.06 million shares, a decrease of 2.54 million shares from the previous period. Hong Kong Central Clearing Limited was the fourth-largest shareholder with 34.73 million shares, down 5.26 million shares [3] - Other notable shareholders include Guangfa Multi-Factor Mixed Fund, which remained unchanged at 24.23 million shares, and ICBC Frontier Medical Stock A, which decreased by 7.01 million shares to 20 million shares [3] - The top ten shareholders also included Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, with holdings of 19.08 million shares and 14.04 million shares, respectively, both showing a decrease compared to the previous period [3]